Pfizer, Starboard

Analysts Rally Around Pfizer CEO Amid Starboard Challenge
Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the company’s leadership. However, analysts are supportive of the embattled executive.
What activist hedge fund Starboard wants from Pfizer
Activist investor Starboard met with Pfizer last week. Here's what went down, according to the hedge fund's cofounder and CEO Jeff Smith.
Starboard Value CEO says Pfizer's board should hold management accountable
Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold management accountable for its underperformance, particularly for its record for producing profitable new drugs.
UPDATED: Starboard wants to hold Pfizer leadership 'accountable' for overpaid M&A deals, poor return on R&D investment
Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job. | Activist investor Starboard Value is baring its teeth at Pfizer management,
Starboard urges Pfizer board to ‘hold management accountable’, FT reports
Activist investor Starboard Value urged Pfizer’s (PFE) leadership to do “something different” and hold management accountable
Starboard calls for Pfizer board to ‘hold management accountable’
Jeff Smith says pharma giant’s returns from recent efforts are ‘not adequate’ in speech at 13D activist investor conference
Pfizer has “significantly overpaid” for recent acquisitions: Starboard Value
Pfizer (PFE) faces renewed calls for change as Jeffrey Smith, CEO of Starboard Value makes his case for his activist stance on the pharma giant. Read more here.
MM&M11h
Senators question whether Eli Lilly, Pfizer telehealth platforms are inappropriately incentivizing prescriptions
As more Big Pharma companies have launched direct-to-consumer telehealth platforms, lawmakers have raised concerns they might ...
A Pfight At Pfizer
There's some rumbling going on within Pfizer's investment community, as an activist hedge fund says that the company's ...
STAT1d
Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions
STAT's Readout LOUD podcast discusses Pfizer's woes, explains RFK Jr.'s 'MAHA' campaign, and mulls the latest about the Novo ...
Pfizer, Merck Pneumonia Shots Get Backing for Adults Over 50
A key panel of US health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc. and ...
Pfizer Q3 Preview: Why The Stock Is A Buy Ahead Of Earnings
Pfizer's Q3 consensus estimate is likely to be exceeded. Despite the underperformance over the past two months, see why PFE ...
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...
BioPharma Dive2d
Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
An Activist Makes the Case Against Pfizer. CEO Bourla is in His Sights
Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.